New Body Line stock fell 3.45 percent on October 2, 2026.

New Body Line stock (ISIN TN0007540016) was last at TND 2.800 on the Tunis Stock Exchange on October 2, 2026, down 3.45 percent for the session. The company reported a sharp first-half contraction, with revenue falling 41 percent to TND 2.6 million for the six months ended June 30, 2026, according to TeraFinances on September 18, 2026.

Revenue falls across exports

The export business generated TND 2.3 million in the first half, down 47 percent from the year-earlier period. Local sales increased from TND 109.0 thousand to TND 329.3 thousand, but their smaller base did not offset the export decline, TeraFinances reported.

Operating pressure also spread through profitability. EBITDA fell 84 percent to TND 161.0 thousand, while operating profit declined 75 percent to TND 110.8 thousand in the first half of 2026.

Profit drops to TND 169.1 thousand

Net income reached TND 169.1 thousand, down 71 percent from TND 580.9 thousand in the first half of 2025. Earnings per share decreased to TND 0.04 from TND 0.14, a comparison that shows the effect of weaker export demand and largely stable payroll costs.

The balance sheet offers a counterweight to the earnings decline. Gross financial debt was zero, while net cash fell from TND 1.7 million at the end of 2025 to TND 1.3 million at June 30, 2026, according to TeraFinances.

Stock remains below its 2025 close

The October 2 price of TND 2.800 stood 30.9 percent below New Body Line's TND 4.050 2025 close and left the stock down 36.9 percent year to date. Mizen's Tunis Stock Exchange table also placed the company's market capitalization at TND 12.0 million on October 2, 2026.

The market is therefore weighing a smaller export business against a debt-free balance sheet. The next decisive operating signal is whether export revenue can recover enough to absorb the company's largely stable cost base.

More news and analyses on New Body Line stock